Physician Assistant Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stacey Tien

Vascular Surgery Orange, CA Physician Assistant

NPI 1770583056 CMS profile 641814

1140 W La Veta Ave, Ste. 850, Orange, CA 92868

Open in the dashboard

General payments

$1,489

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stacey Tien of Orange, CA is reported in the CMS Open Payments database as having received $1,489 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 26th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $376 9
2024 General $539 13
2023 General $117 5
2022 General $239 8
2021 General $191 10
2019 General $28 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacey Tien
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Stacey Tien were reported at $376. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Stacey Tien Vascular Surgery median Middle half National median
2019 $28 $796 $226–$2,363 $163
2020 $0 $348 $118–$1,110 $114
2021 $191 $471 $158–$1,421 $132
2022 $239 $725 $222–$2,183 $149
2023 $117 $836 $257–$2,440 $160
2024 $539 $909 $252–$2,619 $164
2025 $376 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $191 3 payments
  2. Silk Road Medical, Inc. $166 4 payments
  3. Penumbra, Inc. $129 1 payment
  4. Boston Scientific Corporation $108 1 payment
  5. Janssen Pharmaceuticals, Inc $103 5 payments
  6. MIMEDX Group, Inc. $102 4 payments
  7. Pfizer Inc. $88 4 payments
  8. W. L. Gore & Associates, Inc. $86 2 payments
  9. Surmodics, Inc. $72 3 payments
  10. Abbott Laboratories $69 3 payments
  11. Other $375 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,489 46 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Neuroprotection System $166 4 payments
  2. ENROUTE Transcarotid Stent $166 4 payments
  3. ENDURANT IIS $155 1 payment
  4. Indigo System $129 1 payment
  5. Varithena Administration Pack $108 1 payment
  6. XARELTO $103 5 payments
  7. ELIQUIS $88 4 payments
  8. EXCLUDER Conformable AAA Endoprosthesis with Active Control $86 2 payments
  9. Pounce Thrombectomy System $72 3 payments
  10. Pounce Thrombectomy $72 3 payments
  11. Other $845 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

287

Median for Physician Assistant: 241

Drug cost

$24,915

Median for Physician Assistant: $4,110

Branded share of claims

51.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 23 $15,047
Santyl Collagenase Clostridium Hist. Brand 14 $9,220
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 84 $342
Clopidogrel Clopidogrel Bisulfate Brand 17 $96
Diazepam Generic 67 $64
Cephalexin Generic 14 $59
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $42
Lorazepam Generic 43 $27
Tramadol Hcl Generic 14 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$4,045

Medicare's payments for the services billed

Medicare patients

37

Average age 70

Services billed

51

16 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 75%
Heart failure 62%
Ischemic heart disease 62%
Depression 49%
Arthritis 49%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record